Aptevo Therapeutics Inc (APVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has a cash flow conversion efficiency ratio of -0.686x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.96 Million) by net assets ($11.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Aptevo Therapeutics Inc for the company's overall valuation and market capitalisation.
Aptevo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Aptevo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aptevo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptevo Therapeutics Inc ranked by their cash flow conversion efficiency. Explore APVO operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volta Finance Ltd
LSE:VTAS
|
0.057x |
|
Amedeo Air Four Plus Limited
LSE:AA4
|
0.270x |
|
Olivers Real Food Ltd
AU:OLI
|
-0.053x |
|
Site Group International Ltd
AU:SIT
|
0.088x |
|
Baronsmead Second Venture Trust Plc
LSE:BMD
|
-0.010x |
|
Easson Holdings Ltd
PA:MLEAS
|
N/A |
|
Vp plc
LSE:VP
|
0.245x |
|
Jost AG
MU:JOX
|
N/A |
Annual Cash Flow Conversion Efficiency for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Aptevo Therapeutics Inc from 2014 to 2025. View today's stock price for Aptevo Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.38 Million | $-25.59 Million | -1.472x | +70.56% |
| 2024-12-31 | $4.75 Million | $-23.79 Million | -5.002x | -421.15% |
| 2023-12-31 | $12.22 Million | $-11.73 Million | -0.960x | +17.93% |
| 2022-12-31 | $17.97 Million | $-21.02 Million | -1.170x | +93.44% |
| 2021-12-31 | $1.22 Million | $-21.68 Million | -17.828x | -909.07% |
| 2020-12-31 | $16.59 Million | $-29.32 Million | -1.767x | +50.64% |
| 2019-12-31 | $11.84 Million | $-42.38 Million | -3.579x | -111.63% |
| 2018-12-31 | $30.41 Million | $-51.42 Million | -1.691x | -233.72% |
| 2017-12-31 | $82.03 Million | $-41.57 Million | -0.507x | +30.48% |
| 2016-12-31 | $50.57 Million | $-36.86 Million | -0.729x | -32.49% |
| 2015-12-31 | $88.62 Million | $-48.76 Million | -0.550x | -10.74% |
| 2014-12-31 | $94.61 Million | $-47.01 Million | -0.497x | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more